Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib

Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib
February 09, 2021
In a first, Indian scientists develop oral drug for relapsed or refractory MZL, FL
In a major breakthrough in cancer treatment, Alembic Pharmaceutical’s co-owned Rhizen Pharmaceuticals has received US drug regulator - US Food and Drug Administration (USFDA)’s approval for novel next generation oral inhibitor of phosphoinositide 3 kinase (PI3K) delta - Umbralisib for treatment of relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL).
Umbralisib will be marketed by Nasdaq-listed TG Therapeutics, which led its clinical development, under the brand name of Ukoniq. Rhizen Pharmaceuticals co-owned by Alembic Pharmaceuticals with 50 per cent% stake and the rest by Dr Swaroop Vakkalanka, who is President & CEO of the company.

Related Keywords

Australia ,New Zealand ,India ,Rhizen Pharma ,Pranav Amin ,Swaroop Vakkalanka ,Rhizen Pharmaceuticals ,Alembic Pharmaceuticals ,Drug Administration ,Alembic Pharmaceuticals Ltd ,Also Rhizen ,Managing Director ,Breakthrough Therapy Designation ,Usfda ,Cancer Drug ,Umbralisib ,ஆஸ்திரேலியா ,புதியது ஜீலாந்து ,இந்தியா ,பிரணவ் அமின் ,அலெம்பிக் மருந்துகள் ,அலெம்பிக் மருந்துகள் லிமிடெட் ,நிர்வகித்தல் இயக்குனர் ,திருப்புமுனை சிகிச்சை பதவி ,புற்றுநோய் மருந்து ,